Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 181

1.

Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer.

Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A.

Carcinogenesis. 2000 Feb;21(2):147-51.

PMID:
10657950
[PubMed - indexed for MEDLINE]
Free Article
2.

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG.

J Natl Cancer Inst. 2000 Apr 5;92(7):564-9.

PMID:
10749912
[PubMed - indexed for MEDLINE]
Free Article
3.

BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.

Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY.

Cancer Res. 2000 Oct 1;60(19):5329-33.

PMID:
11034065
[PubMed - indexed for MEDLINE]
Free Article
4.

Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.

Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F.

Oncogene. 2001 Mar 22;20(12):1509-18.

PMID:
11313894
[PubMed - indexed for MEDLINE]
Free Article
5.

High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.

Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA.

Cancer Genet Cytogenet. 2005 Jun;159(2):114-22.

PMID:
15899382
[PubMed - indexed for MEDLINE]
6.

Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.

Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P.

Cancer Res. 2008 Feb 15;68(4):998-1002. doi: 10.1158/0008-5472.CAN-07-2418.

PMID:
18281473
[PubMed - indexed for MEDLINE]
Free Article
7.

Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.

Chan KY, Ozçelik H, Cheung AN, Ngan HY, Khoo US.

Cancer Res. 2002 Jul 15;62(14):4151-6.

PMID:
12124354
[PubMed - indexed for MEDLINE]
Free Article
8.

Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.

Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE.

Breast Cancer Res. 2006;8(4):R38.

PMID:
16846527
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens.

Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW.

Carcinogenesis. 2000 Sep;21(9):1761-5.

PMID:
10964110
[PubMed - indexed for MEDLINE]
Free Article
10.

Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.

Miyamoto K, Fukutomi T, Asada K, Wakazono K, Tsuda H, Asahara T, Sugimura T, Ushijima T.

Jpn J Clin Oncol. 2002 Mar;32(3):79-84.

PMID:
11956301
[PubMed - indexed for MEDLINE]
Free Article
11.

Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.

Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, Katsuyama Y, Konishi I.

J Pathol. 2004 Feb;202(2):215-23.

PMID:
14743504
[PubMed - indexed for MEDLINE]
12.

Methylation of the BRCA1 gene in sporadic breast cancer.

Dobrovic A, Simpfendorfer D.

Cancer Res. 1997 Aug 15;57(16):3347-50.

PMID:
9269993
[PubMed - indexed for MEDLINE]
Free Article
13.

CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.

Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, Xing W, Archer TK.

Oncogene. 1998 Mar 5;16(9):1161-9.

PMID:
9528858
[PubMed - indexed for MEDLINE]
Free Article
14.

Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.

Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E.

Breast Cancer Res. 2008;10(5):R82. doi: 10.1186/bcr2151. Epub 2008 Sep 30.

PMID:
18826564
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Inactivation of BRCA1 and BRCA2 in ovarian cancer.

Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE.

J Natl Cancer Inst. 2002 Sep 18;94(18):1396-406.

PMID:
12237285
[PubMed - indexed for MEDLINE]
Free Article
16.

DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter.

Butcher DT, Mancini-DiNardo DN, Archer TK, Rodenhiser DI.

Int J Cancer. 2004 Sep 20;111(5):669-78.

PMID:
15252835
[PubMed - indexed for MEDLINE]
17.

Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer.

Zhao L, Wang L, Jin F, Ma W, Ren J, Wen X, He M, Sun M, Tang H, Wei M.

Breast Cancer Res Treat. 2009 Sep;117(2):253-9. doi: 10.1007/s10549-008-0192-1. Epub 2008 Sep 24.

PMID:
18814026
[PubMed - indexed for MEDLINE]
18.

BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.

Chiang JW, Karlan BY, Cass L, Baldwin RL.

Gynecol Oncol. 2006 Jun;101(3):403-10. Epub 2005 Dec 19.

PMID:
16360812
[PubMed - indexed for MEDLINE]
19.

Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.

Rice JC, Massey-Brown KS, Futscher BW.

Oncogene. 1998 Oct 8;17(14):1807-12.

PMID:
9778046
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk